Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis | Zendy

Michihisa Moriguchi | Zendy; Takeshi Aramaki | Zendy; Hideyuki Nishiofuku | Zendy; Rui Sato | Zendy; Koiku Asakura | Zendy; Kanji Yamaguchi | Zendy; Toshihiro Tanaka | Zendy; Masahiro Endo | Zendy; Yoshito Itoh | Zendy

Open Access

Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis

Author(s) -

Michihisa Moriguchi,

Takeshi Aramaki,

Hideyuki Nishiofuku,

Rui Sato,

Koiku Asakura,

Kanji Yamaguchi,

Toshihiro Tanaka,

Masahiro Endo,

Yoshito Itoh

Publication year - 2017

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000473887

Subject(s) - sorafenib , hepatocellular carcinoma , medicine , portal vein thrombosis , gastroenterology , portal vein , cisplatin , thrombosis , chemotherapy , liver cancer

To investigate the validity of hepatic arterial infusion chemotherapy with low-dose 5-fluorouracil and cisplatin (LFP) versus sorafenib as first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (Vp3, Vp4).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research